{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "ECT",
      "effectiveness",
      "functional disability",
      "major depression",
      "naturalistic study"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "L\u2019efficacit\u00e9 de la TEC dans des conditions naturalistes n\u2019a pas \u00e9t\u00e9 bien \u00e9tudi\u00e9e. La pr\u00e9sente \u00e9tude visait \u00e0 1) caract\u00e9riser un \u00e9chantillon naturaliste de patients de la TEC; et 2) examiner les r\u00e9sultats \u00e0 long terme de la TEC sur les sympt\u00f4mes d\u00e9pressifs (Inventaire de la d\u00e9pression de Beck-II; IDB-II) et les sympt\u00f4mes d\u2019incapacit\u00e9 fonctionnelle (Programme d\u2019\u00e9valuation du handicap de l\u2019OMS 2.0) dans cet \u00e9chantillon.",
        "Les participants \u00e9taient des adultes qui ont re\u00e7u la TEC pour un \u00e9pisode de d\u00e9pression majeure \u00e0 une clinique ambulatoire de TEC entre septembre 2010 et novembre 2020. Les \u00e9valuations cliniques et cognitives ont \u00e9t\u00e9 men\u00e9es au d\u00e9part (<i>n</i>\u2009=\u2009100), au milieu de la TEC (<i>n</i>\u2009=\u200994), 2 \u00e0 4 semaines apr\u00e8s la TEC (<i>n</i>\u2009=\u200964), 6 mois apr\u00e8s la TEC (<i>n</i>\u2009=\u200934), et 12 mois apr\u00e8s la TEC (<i>n</i>\u2009=\u200919).",
        "Au d\u00e9part, les participants avaient des niveaux graves de sympt\u00f4mes d\u00e9pressifs (IDB-II : <i>M</i>\u2009=\u200941,0; <i>ET</i>\u2009=\u20099,4), et 62,9% avaient un d\u00e9pistage positif pour de multiples diagnostics psychiatriques du Mini-Entretien Neuropsychiatrique International. Les sympt\u00f4mes d\u00e9pressifs (<i>F</i>(4,49,1)\u2009=\u200949,92, <i>p</i>\u2009<i><</i>\u20090.001) et les sympt\u00f4mes d\u2019incapacit\u00e9 <i>F</i>(3,40,72)\u2009=\u200912,30, <i>p</i>\u2009<i><</i>\u20090.001) s\u2019am\u00e9lioraient significativement apr\u00e8s la TEC, ce qui \u00e9tait maintenu au suivi de 12 mois. L\u2019am\u00e9lioration des sympt\u00f4mes d\u00e9pressifs avait tendance \u00e0 pr\u00e9dire significativement la r\u00e9duction des sympt\u00f4mes d\u2019incapacit\u00e9 du d\u00e9part jusqu\u2019apr\u00e8s la TEC, (<i>F</i>(1,56)\u2009=\u20093,67, <i>p</i>\u2009<i>=</i>\u2009<i>,</i>061). Bien que notre taux de r\u00e9mission clinique de 27% (score \u00e0 l\u2019IDB-II <math xmlns=\"http://www.w3.org/1998/Math/MathML\"><mo>\u2264</mo></math> 13 et am\u00e9lioration \u00e0 <math xmlns=\"http://www.w3.org/1998/Math/MathML\"><mo>\u2265</mo></math> 50%) et le taux de r\u00e9ponse global de 41,3% ( <math xmlns=\"http://www.w3.org/1998/Math/MathML\"><mo>\u2265</mo></math> 50% d\u2019am\u00e9lioration au score de l\u2019IDB-II) aient \u00e9t\u00e9 plus faibles que les taux indiqu\u00e9s dans l\u2019essai randomis\u00e9 contr\u00f4l\u00e9 existant et la litt\u00e9rature communautaire de la TEC, 36% de ceux trait\u00e9s par la TEC ont \u00e9t\u00e9 perdus au suivi et n\u2019ont pas r\u00e9pondu aux \u00e9chelles d\u2019\u00e9valuation post-TEC. Au d\u00e9part, ceux qui \u00e9taient en r\u00e9mission avaient significativement moins de comorbidit\u00e9s psychiatriques, des scores plus faibles \u00e0 l\u2019IDB-II, et des sympt\u00f4mes d\u2019incapacit\u00e9 plus faibles que les non-r\u00e9pondants (<i>p</i>\u2009<\u20090.05).",
        "Les participants \u00e9taient gravement symptomatiques et cliniquement complexes. La TEC \u00e9tait efficace pour r\u00e9duire les sympt\u00f4mes d\u00e9pressifs et de l\u2019incapacit\u00e9 fonctionnelle dans cet \u00e9chantillon h\u00e9t\u00e9rog\u00e8ne. Bien qu\u2019une grande quantit\u00e9 de donn\u00e9es manquantes puisse avoir fauss\u00e9 notre r\u00e9ponse calcul\u00e9e/taux de r\u00e9mission, il est \u00e9galement probable que l\u2019h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 et la gravit\u00e9 clinique contribuent \u00e0 une r\u00e9mission plus faible que pr\u00e9vu et aux taux de r\u00e9ponse \u00e0 la TEC."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34903092",
  "DateCompleted": {
    "Year": "2022",
    "Month": "05",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "09",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "12",
        "Day": "13"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1177/07067437211064020"
    ],
    "Journal": {
      "ISSN": "1497-0015",
      "JournalIssue": {
        "Volume": "67",
        "Issue": "5",
        "PubDate": {
          "Year": "2022",
          "Month": "May"
        }
      },
      "Title": "Canadian journal of psychiatry. Revue canadienne de psychiatrie",
      "ISOAbbreviation": "Can J Psychiatry"
    },
    "ArticleTitle": "Naturalistic Study on the Effects of Electroconvulsive Therapy (ECT) on Depressive Symptoms.",
    "Pagination": {
      "StartPage": "351",
      "EndPage": "360",
      "MedlinePgn": "351-360"
    },
    "Abstract": {
      "AbstractText": [
        "The effectiveness of ECT under naturalistic conditions has not been well-studied. The current study aimed to 1) characterize a naturalistic sample of ECT patients; and 2) examine the long-term outcomes of ECT on depressive symptoms (Beck Depression Inventory-II; BDI-II) and functional disability symptoms (WHO Disability Assessment Schedule 2.0) in this sample.",
        "Participants were adults who received ECT for a major depressive episode at an ambulatory ECT clinic between September 2010 and November 2020. Clinical and cognitive assessments were completed at baseline (<i>n</i>\u2009=\u2009100), mid-ECT (<i>n</i>\u2009=\u200994), 2-4 weeks post-ECT (<i>n</i>\u2009=\u200964), 6-months post-ECT (<i>n</i>\u2009=\u200934), and 12-months post-ECT (<i>n</i>\u2009=\u200919).",
        "At baseline, participants had severe levels of depressive symptoms (BDI-II: <i>M</i>\u2009=\u200941.0, <i>SD</i>\u2009=\u20099.4), and 62.9% screened positive for multiple psychiatric diagnoses on the MINI International Neuropsychiatric Interview. Depressive symptoms (<i>F</i>(4,49.1)\u2009=\u200949.92, <i>P</i>\u2009<i><</i>\u20090.001) and disability symptoms (<i>F</i>(3,40.72)\u2009=\u200912.30, <i>P</i>\u2009<i><</i>\u20090.001) improved significantly following ECT, and this was maintained at 12-months follow-up. Improvement in depressive symptoms trended towards significantly predicting reduction in disability symptoms from baseline to post-ECT, (<i>F</i>(1,56)\u2009=\u20093.67, <i>P</i>\u2009<i>=</i>\u20090.061). Although our clinical remission rate of 27% (BDI-II score <math xmlns=\"http://www.w3.org/1998/Math/MathML\"><mo>\u2264</mo></math> 13 and <math xmlns=\"http://www.w3.org/1998/Math/MathML\"><mo>\u2265</mo></math> 50% improvement) and overall response rate of 41.3% (<math xmlns=\"http://www.w3.org/1998/Math/MathML\"><mo>\u2265</mo></math>50% improvement in BDI-II score) were lower than the rates reported in the extant RCT and community ECT literature, 36% of those treated with ECT were lost to follow-up and did not complete post-ECT rating scales. At baseline, remitters had significantly fewer psychiatric comorbidities, lower BDI-II scores, and lower disability symptoms than non-responders (<i>P</i>\u2009<\u20090.05).",
        "Participants were severely symptomatic and clinically complex. ECT was effective at reducing depressive symptoms and functional disability in this heterogeneous sample. Although a large amount of missing data may have distorted our calculated response/remission rates, it is also likely that clinical heterogeneity and severity contribute to lower-than-expected remission and response rates to ECT."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-0631-0694"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychology, Neuroscience & Behaviour, 3710McMaster University, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Clinical Neuropsychology Service, St. Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada."
          }
        ],
        "LastName": "Goegan",
        "ForeName": "Sarah A",
        "Initials": "SA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, 3710McMaster University, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "ECT Clinic, St, Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Mood Disorders Program, St. Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada."
          }
        ],
        "LastName": "Hasey",
        "ForeName": "Gary M",
        "Initials": "GM"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychology, Neuroscience & Behaviour, 3710McMaster University, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Clinical Neuropsychology Service, St. Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, 3710McMaster University, Hamilton, Ontario, Canada."
          }
        ],
        "LastName": "King",
        "ForeName": "Jelena P",
        "Initials": "JP"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, 3710McMaster University, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Forensic Psychiatry Program, St. 228603Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada."
          }
        ],
        "LastName": "Losier",
        "ForeName": "Bruno J",
        "Initials": "BJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinical Neuropsychology Service, St. Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, 3710McMaster University, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Mood Disorders Program, St. Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada."
          }
        ],
        "LastName": "Bieling",
        "ForeName": "Peter J",
        "Initials": "PJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychology, Neuroscience & Behaviour, 3710McMaster University, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, 3710McMaster University, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Mood Disorders Program, St. Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "585565Homewood Research Institute, Guelph, Ontario, Canada."
          }
        ],
        "LastName": "McKinnon",
        "ForeName": "Margaret C",
        "Initials": "MC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Psychology, Neuroscience & Behaviour, 3710McMaster University, Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Clinical Neuropsychology Service, St. Joseph's Healthcare Hamilton (SJHH), Hamilton, Ontario, Canada."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Psychiatry and Behavioural Neurosciences, 3710McMaster University, Hamilton, Ontario, Canada."
          }
        ],
        "LastName": "McNeely",
        "ForeName": "Heather E",
        "Initials": "HE"
      }
    ],
    "GrantList": [
      {
        "Agency": "CIHR",
        "Country": "Canada"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Can J Psychiatry",
    "NlmUniqueID": "7904187",
    "ISSNLinking": "0706-7437"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "therapy"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "psychology",
        "therapy"
      ],
      "DescriptorName": "Depressive Disorder, Major"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Electroconvulsive Therapy"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Psychiatric Status Rating Scales"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ],
  "CoiStatement": "<b>Declaration of Conflicting Interests:</b> The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."
}